Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM deal
Mentari raised $200M for its migraine program while Royalty Pharma announced a new ATTR-CM deal.
Mentari
Private
Mentari is a biotechnology company focused on developing therapies for migraine and related neurological disorders.
Company Info
Sector:Biotechnology
Headquarters:Cambridge, Massachusetts, USA
Founded:2022
Website:mentaritx.com/
Funding Round:Series A
Total Funding:$200M (Series A, July 2026)
Upcoming Milestones & Key Dates
Q4 2026
Clinical
Phase 1 readout
Clinical Development Pipeline
MNT-101
Target: CGRP receptorUndisclosed
Target: TBDUndisclosed
Target: TBDRecent News
Leadership Team
To be confirmed
Chief Executive Officer
To be confirmed
Chief Medical Officer
To be confirmed
Chief Scientific Officer
Careers & Job Openings